The efficacy of tissue factor −603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients
Background and Aim: Venous thromboembolism (VTE) is one of the most common complications in cancer patients. Although factor V Leiden (FVL) is the most common genetic defect causing thrombosis, the impact of gene abnormalities on thrombotic tendency in cancer patients remains poorly explored. Tissue...
Збережено в:
| Дата: | 2016 |
|---|---|
| Автори: | , , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2016
|
| Назва видання: | Experimental Oncology |
| Теми: | |
| Онлайн доступ: | http://dspace.nbuv.gov.ua/handle/123456789/137716 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | The efficacy of tissue factor −603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients / A. Eroğlu, G.G. Ceylan, E. Ozturk, A. Yalcin, B. Yalcin, D. Karasoy // Experimental Oncology. — 2016 — Т. 38, № 3. — С. 187-190. — Бібліогр.: 27 назв. — англ. |
Репозитарії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| id |
irk-123456789-137716 |
|---|---|
| record_format |
dspace |
| institution |
Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| collection |
DSpace DC |
| language |
English |
| topic |
Original contributions Original contributions |
| spellingShingle |
Original contributions Original contributions Eroğlu, A. Ceylan, G.G. Ozturk, E. Yalcin, A. Yalcin, B. Karasoy, D. The efficacy of tissue factor −603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients Experimental Oncology |
| description |
Background and Aim: Venous thromboembolism (VTE) is one of the most common complications in cancer patients. Although factor V Leiden (FVL) is the most common genetic defect causing thrombosis, the impact of gene abnormalities on thrombotic tendency in cancer patients remains poorly explored. Tissue factor (TF) is a major physiologic initiator of blood coagulation. This is the first study regarding the association of TF gene −603A/G and +5466A>G polymorphisms with VTE in malignancy. Materials and Me thods: The study consists of two groups: cancer patients with VTE were included as Group 1 (n = 46); Group 2 comprises 196 cancer patients without VTE. Restriction fragment length polymorphism method was used for the detection of polymorphisms of TF −603A/G in the 5՛upstream region and TF 5466A/G in intron 2. FVL, PT G20210A and MTHFR C677T polymorphisms were determined by using commercially available Light Cycler kits. The genotype and allele frequencies between the groups were compared using χ² or Fisher exact test, if appropriate. Results: No differences were observed in the distribution of TF gene −603A/G genotype frequencies between the groups. Although a slightly increased incidence of +5466GA genotype was in Group 1 (17.4% vs 11.2%), it did not achieve statistical significance. The prevalence of FVL was significantly greater in Group 1 compared with Group 2 (41.3% vs 4.1%, p < 0.05). Difference in frequency of 677TT+CT (MTHFR) + 5466GG (TF) genotypes combination was found in women of two investigated Groups (p < 0.05). No differences were also in genotypes and allele frequencies of MTHFR C677T and PT G20210A between two Groups (p > 0.05). Conclusions: The present study did not show significant association of TF gene −603A/G and +5466A>G polymorphisms with VTE in malignancy, however, further larger studies including different ethnic population are needed to confirm our findings. |
| format |
Article |
| author |
Eroğlu, A. Ceylan, G.G. Ozturk, E. Yalcin, A. Yalcin, B. Karasoy, D. |
| author_facet |
Eroğlu, A. Ceylan, G.G. Ozturk, E. Yalcin, A. Yalcin, B. Karasoy, D. |
| author_sort |
Eroğlu, A. |
| title |
The efficacy of tissue factor −603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients |
| title_short |
The efficacy of tissue factor −603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients |
| title_full |
The efficacy of tissue factor −603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients |
| title_fullStr |
The efficacy of tissue factor −603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients |
| title_full_unstemmed |
The efficacy of tissue factor −603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients |
| title_sort |
efficacy of tissue factor −603a/g and +5466a>g polimorphisms at the development of venous thromboembolism in cancer patients |
| publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| publishDate |
2016 |
| topic_facet |
Original contributions |
| url |
http://dspace.nbuv.gov.ua/handle/123456789/137716 |
| citation_txt |
The efficacy of tissue factor −603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients / A. Eroğlu, G.G. Ceylan, E. Ozturk, A. Yalcin, B. Yalcin, D. Karasoy // Experimental Oncology. — 2016 — Т. 38, № 3. — С. 187-190. — Бібліогр.: 27 назв. — англ. |
| series |
Experimental Oncology |
| work_keys_str_mv |
AT eroglua theefficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients AT ceylangg theefficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients AT ozturke theefficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients AT yalcina theefficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients AT yalcinb theefficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients AT karasoyd theefficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients AT eroglua efficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients AT ceylangg efficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients AT ozturke efficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients AT yalcina efficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients AT yalcinb efficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients AT karasoyd efficacyoftissuefactor603agand5466agpolimorphismsatthedevelopmentofvenousthromboembolismincancerpatients |
| first_indexed |
2023-10-18T21:14:47Z |
| last_indexed |
2023-10-18T21:14:47Z |
| _version_ |
1796152312524177408 |
| spelling |
irk-123456789-1377162018-06-18T03:06:06Z The efficacy of tissue factor −603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients Eroğlu, A. Ceylan, G.G. Ozturk, E. Yalcin, A. Yalcin, B. Karasoy, D. Original contributions Background and Aim: Venous thromboembolism (VTE) is one of the most common complications in cancer patients. Although factor V Leiden (FVL) is the most common genetic defect causing thrombosis, the impact of gene abnormalities on thrombotic tendency in cancer patients remains poorly explored. Tissue factor (TF) is a major physiologic initiator of blood coagulation. This is the first study regarding the association of TF gene −603A/G and +5466A>G polymorphisms with VTE in malignancy. Materials and Me thods: The study consists of two groups: cancer patients with VTE were included as Group 1 (n = 46); Group 2 comprises 196 cancer patients without VTE. Restriction fragment length polymorphism method was used for the detection of polymorphisms of TF −603A/G in the 5՛upstream region and TF 5466A/G in intron 2. FVL, PT G20210A and MTHFR C677T polymorphisms were determined by using commercially available Light Cycler kits. The genotype and allele frequencies between the groups were compared using χ² or Fisher exact test, if appropriate. Results: No differences were observed in the distribution of TF gene −603A/G genotype frequencies between the groups. Although a slightly increased incidence of +5466GA genotype was in Group 1 (17.4% vs 11.2%), it did not achieve statistical significance. The prevalence of FVL was significantly greater in Group 1 compared with Group 2 (41.3% vs 4.1%, p < 0.05). Difference in frequency of 677TT+CT (MTHFR) + 5466GG (TF) genotypes combination was found in women of two investigated Groups (p < 0.05). No differences were also in genotypes and allele frequencies of MTHFR C677T and PT G20210A between two Groups (p > 0.05). Conclusions: The present study did not show significant association of TF gene −603A/G and +5466A>G polymorphisms with VTE in malignancy, however, further larger studies including different ethnic population are needed to confirm our findings. Background and Aim: Venous thromboembolism (VTE) is one of the most common complications in cancer patients. Although factor V Leiden (FVL) is the most common genetic defect causing thrombosis, the impact of gene abnormalities on thrombotic tendency in cancer patients remains poorly explored. Tissue factor (TF) is a major physiologic initiator of blood coagulation. This is the first study regarding the association of TF gene −603A/G and +5466A>G polymorphisms with VTE in malignancy. Materials and Me thods: The study consists of two groups: cancer patients with VTE were included as Group 1 (n = 46); Group 2 comprises 196 cancer patients without VTE. Restriction fragment length polymorphism method was used for the detection of polymorphisms of TF −603A/G in the 5՛upstream region and TF 5466A/G in intron 2. FVL, PT G20210A and MTHFR C677T polymorphisms were determined by using commercially available Light Cycler kits. The genotype and allele frequencies between the groups were compared using χ² or Fisher exact test, if appropriate. Results: No differences were observed in the distribution of TF gene −603A/G genotype frequencies between the groups. Although a slightly increased incidence of +5466GA genotype was in Group 1 (17.4% vs 11.2%), it did not achieve statistical significance. The prevalence of FVL was significantly greater in Group 1 compared with Group 2 (41.3% vs 4.1%, p < 0.05). Difference in frequency of 677TT+CT (MTHFR) + 5466GG (TF) genotypes combination was found in women of two investigated Groups (p < 0.05). No differences were also in genotypes and allele frequencies of MTHFR C677T and PT G20210A between two Groups (p > 0.05). Conclusions: The present study did not show significant association of TF gene −603A/G and +5466A>G polymorphisms with VTE in malignancy, however, further larger studies including different ethnic population are needed to confirm our findings. 2016 Article The efficacy of tissue factor −603A/G and +5466A>G polimorphisms at the development of venous thromboembolism in cancer patients / A. Eroğlu, G.G. Ceylan, E. Ozturk, A. Yalcin, B. Yalcin, D. Karasoy // Experimental Oncology. — 2016 — Т. 38, № 3. — С. 187-190. — Бібліогр.: 27 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/137716 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |